Imperial College London
Portrait Picture

ProfessorPaoloMuraro

Faculty of Medicine, Department of Brain Sciences

Professor of Neurology - Neuroimmunology and Immunotherapy
 
 
 
//

Contact

 

p.muraro Website

 
 
//

Assistant

 

Mrs Gearoidin Beazley +44 (0)20 7594 7047

 
//

Location

 

E415Burlington DanesHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Scalfari:2018:10.17925/enr.2018.13.2.78,
author = {Scalfari, A and Muraro, PA},
doi = {10.17925/enr.2018.13.2.78},
journal = {European Neurological Review},
pages = {78--85},
title = {Monoclonal antibody therapy and long-term outcomes in multiple sclerosis - The challenge of treatment optimisation},
url = {http://dx.doi.org/10.17925/enr.2018.13.2.78},
volume = {13},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The therapeutic landscape of multiple sclerosis (MS) has been transformed by the advent of several new monoclonal antibody (MAb) therapies that can potentially lead to full stabilisation of detectable disease activity. Natalizumab, alemtuzumab and ocrelizumab are currently licensed MAbs for the treatment of MS. Daclizumab was licensed for the treatment of MS, although it has been recently withdrawn from the market by the manufacturer. Most patients are initially managed with first-line treatments, and, if disease breakthrough occurs, are escalated to a stronger compound, yet the available evidence indicates an early window of therapeutic opportunity for MAbs to exert most of their efficacy. It is important to balance the superior efficacy of MAbs compared with injectable treatments against more serious side effects, although these are well recognised and can be monitored where indicated and treated. In particular, the risk of progressive multifocal leucoencephalopathy with natalizumab can be managed by screening potential patients for the John Cunningham virus. The MAbs also have the benefit of convenience to patients compared with daily or weekly treatments since they are given via less frequent administration. The cost of these treatments, compared with other therapies, may be an important issue in many countries where healthcare budgets are under pressure. The complex decision of choosing the best treatment for an individual should be made jointly between the doctor and the patient after careful consideration of the many factors to be weighed.
AU  - Scalfari,A
AU  - Muraro,PA
DO  - 10.17925/enr.2018.13.2.78
EP  - 85
PY  - 2018///
SN  - 1758-3837
SP  - 78
TI  - Monoclonal antibody therapy and long-term outcomes in multiple sclerosis - The challenge of treatment optimisation
T2  - European Neurological Review
UR  - http://dx.doi.org/10.17925/enr.2018.13.2.78
VL  - 13
ER  -
Download